Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.73 |
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | XDH | P47989 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28710571 | 0.80 | POLB (0.51) | POLBLMNAALDH1A1RAB9AKMT2A | |
| SCHEMBL10745547 | 0.79 | CA12 (0.55) | POLBCA1CA2CA12CA7 | |
| SCHEMBL30910235 | 0.79 | POLB (0.51) | POLBCA1CA2CA12CA9 | |
| SCHEMBL1680458 | 0.79 | CA12 (0.55) | POLBCA1CA2CA12CA7 | |
| SCHEMBL16891486 | 0.77 | POLB (0.49) | POLBLMNAMAPTALDH1A1RAB9A | |
| SCHEMBL657937 | 0.77 | POLB (0.47) | POLBLMNAMAPTALDH1A1RAB9A | |
| SCHEMBL447082 | 0.76 | L3MBTL1 (0.51) | POLBLMNATSHRRAB9AKMT2A | |
| SCHEMBL8985224 | 0.76 | POLB (0.48) | POLBCA1CA2CA12CA7 | |
| SCHEMBL8985228 | 0.76 | POLB (0.48) | POLBCA1CA2CA12CA7 | |
| SCHEMBL12376722 | 0.76 | SMN1; SMN2 (0.59) | POLBLMNAMAPTALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 216 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739685-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | Janssen Pharmaceutica NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| EP-4704830-A2 | MRGPRX2 INHIBITORS AND METHODS OF USE THEREOF | Septerna, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4313981-B1 | 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS | PFIZER (US) | 2026-02-25 | — | — | EP | disclosed |
| WO-2025262297-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | DARK BLUE THERAPEUTICS LTD (GB) | 2025-12-26 | — | — | WO | disclosed |
| EP-4667467-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | Dark Blue Therapeutics Ltd (GB) | 2025-12-24 | — | — | EP | disclosed |
| US-12466805-B2 | Pharmaceutical compounds | ALMAC DISCOVERY LIMITED (GB) | 2025-11-11 | — | — | US | disclosed |
| US-20250263411-A1 | 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS | PFIZER INC. (US) | 2025-08-21 | — | — | US | disclosed |
| EP-3762377-B1 | PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND MEDICAL USES THEREOF | UNIV CORNELL (US) | 2025-08-20 | — | — | EP | disclosed |
| EP-4077306-B1 | COMPOUNDS AND PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION INC (US) | 2025-05-07 | — | — | EP | disclosed |
| WO-2025050636-A1 | MACROCYCLIC PYRAZOLOPYRIMIDINE COMPOUND AND USE THEREOF | 浙江养生堂天然药物研究所有限公司 | 2025-03-13 | — | — | WO | disclosed |
| US-20050009879-A1 | Chemical intermediates for their production such as 1-ethyl-2-pyridone-5-carboxylic acid; neuropeptide Y receptor antagonists; for treatment of cardiovascular disorders, glaucoma, and eating disorders | MSD K.K. (JP) | 2005-01-13 | — | — | US | disclosed |
| WO-2004031175-A2 | N-SUBSTITUTED-2-OXODIHYDROPYRIDINE DERIVATIVES AS NPY ANTAGONISTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-04-15 | — | — | WO | disclosed |
| US-20040072874-A1 | N-substituted-2-oxodihydropyridine derivatives | MSD K.K. (JP) | 2004-04-15 | — | — | US | disclosed |
| CN-1075480-A | New aryl carbonylamino alkyl-dihydro-oxo pyridine compounds and production thereof and application | HOECHST AG (US) | 1993-08-25 | — | — | CN | disclosed |
| EP-0190265-B1 | PYRIDONE ESTERS AS INOTROPIC AGENTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-01-08 | — | — | EP | disclosed |
| EP-0190265-A4 | PYRIDONE ESTERS AS INOTROPIC AGENTS. | AMERICAN HOSPITAL SUPPLY CORP (US) | 1987-07-09 | — | — | EP | disclosed |
| US-4657919-A | CARDIOVASCULAR DISORDERS | E. I. DU PONT DE NEMOURS & CO. (US) | 1987-04-14 | — | — | US | disclosed |
| EP-0190265-A1 | PYRIDONE ESTERS AS INOTROPIC AGENTS. | AMERICAN HOSPITAL SUPPLY CORP (US) | 1986-08-13 | — | — | EP | disclosed |
| WO-1986001202-A1 | PYRIDONE ESTERS AS INOTROPIC AGENTS | AMERICAN HOSPITAL SUPPLY CORPORATION (US) | 1986-02-27 | — | — | WO | disclosed |
| US-4555517-A | Pyridone esters as inotropic agents | AMERICAN HOSPITAL SUPPLY CORPORATION (US) | 1985-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12466805-B2 | Pharmaceutical compounds | USP19, USP18, UBE2I | POLB 2873/4885CA1 1661/4885CA2 3007/4885 |
| US-20250263411-A1 | 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS | NRAS, KRAS, BRAF | POLB 1023/4885CA1 4030/4885CA2 3624/4885 |
| US-20050009879-A1 | Chemical intermediates for their production such as 1-ethyl-2-pyridone-5-carboxylic acid; neuropeptide Y receptor antagonists; for treatment of cardiovascular disorders, glaucoma, and eating disorders | NPY1R, NPY2R, NPY4R | POLB 4052/4885CA1 4513/4885CA2 930/4885 |
| US-20040072874-A1 | N-substituted-2-oxodihydropyridine derivatives | GPR119, NPY4R, NPY1R | POLB 3606/4885CA1 4104/4885CA2 1137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.